Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis

scientific article published on 01 April 2006

Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/JNCI/DJJ137
P698PubMed publication ID16622127

P50authorPatrice DubreuilQ30089953
Jean Robert DelperoQ59677704
P2093author name stringYing Yang
Jocelyne Jacquemier
Hagay Sobol
Anthony Gonçalves
Francois Bertucci
Tetsuro Noguchi
Genevieve Monges
Donatella Di Stefano
Fabienne Palmerini
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectimatinibQ177094
P304page(s)562-563
P577publication date2006-04-01
P1433published inJournal of the National Cancer InstituteQ400279
P1476titleResponse of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis
P478volume98

Reverse relations

cites work (P2860)
Q33737479A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
Q37045567AKT1 and BRAF mutations in pediatric aggressive fibromatosis
Q42908309Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects
Q38656475High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature
Q34129408Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
Q34168680Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology
Q35820278KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
Q47157396Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report
Q38736110Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
Q35842446Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
Q36264188Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Search more.